Abstract
Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Current Bioactive Compounds
Title: Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Volume: 2 Issue: 2
Author(s): Hiroyuki Miyachi
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Abstract: Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Export Options
About this article
Cite this article as:
Miyachi Hiroyuki, Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome, Current Bioactive Compounds 2006; 2 (2) . https://dx.doi.org/10.2174/157340706777435176
DOI https://dx.doi.org/10.2174/157340706777435176 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Current Drug Targets Therapeutic Use of Snake Venom Components: A Voyage from Ancient to Modern India
Mini-Reviews in Organic Chemistry Fitness or Fatness - the Debate Continues for the Role of Leptin in Obesity-Associated Heart Dysfunction
Current Diabetes Reviews The Impact of Body Mass Index and Type 2 Diabetes on Breast Cancer: Current Therapeutic Measures of Prevention
Current Drug Targets - Immune, Endocrine & Metabolic Disorders From Raynaud’s Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach
Current Rheumatology Reviews Imaging of Visceral Adipose Tissue: An Emerging Diagnostic Tool and Therapeutic Target
Current Drug Targets - Cardiovascular & Hematological Disorders Insulin Therapy in Cardiac Surgery
Current Diabetes Reviews Reductive Stress: A New Concept in Alzheimer’s Disease
Current Alzheimer Research The Prevention of Preterm Labour - Corticotropin Releasing Hormone Type 1 Receptors as a Target for Drug Design and Development
Mini-Reviews in Medicinal Chemistry QSAR of Antitrypanosomal Activities of Polyphenols and their Analogues Using Multiple Linear Regression and Artificial Neural Networks
Combinatorial Chemistry & High Throughput Screening Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model
Current Drug Delivery Anti-HER2 Cancer Therapy and Cardiotoxicity
Current Pharmaceutical Design 58-Year Old Men with Non-Stenotic Carotid Artery Plaques and the Relationship with Cardiovascular Risk Factors and Future Cardiovascular Events
Vascular Disease Prevention (Discontinued) Meet Our Editor:
Current Clinical Pharmacology Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis
Current Pharmaceutical Design Lipid Mediator Profiling in Pulmonary Disease
Current Pharmaceutical Biotechnology Arterial Spin Labeling Perfusion MRI in Alzheimers Disease
Current Medical Imaging Editorial [ Hot Topic: The Blood-Brain Barrier as a Cause of Disease (Executive Editor: William A. Banks) ]
Current Pharmaceutical Design The Role of Adipokines in Hypertension and Cardiovascular Disease
Current Hypertension Reviews